Hysterectomy or/and lymphadenectomy for the survival of patients with primary endometrial cancer: a cohort study using the SEER database

Min, Yanmei; Zhang, Zhen

doi:10.1080/02648725.2022.2162235

Cited by 4 publications

(2 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Whether endometrial cancer patients require lymphadenectomy or other procedures such as sentinel lymph node mapping, pelvic lymphadenectomy alone or combined pelvic and para-aortic lymphadenectomy is still controversial. [16][17][18] Previously, the presence of lymph node metastasis was identified to influence the prognosis and treatment decisions of patients with endometrial cancer. 19 The molecular subtype and preoperative cancer antigen 125> 25 were significantly associated with lymph node metastasis in patients with endometrial cancer.…”

Section: Discussionmentioning

confidence: 99%

Number of Positive Lymph Nodes and Survival in Endometrial Carcinoma: A Proposal for a Modified Staging

Li,

Zhang,

2024

IJWH

View full text Add to dashboard Cite

Purpose To construct a new clinical staging system including the number of lymph node metastases to supplement the International Federation of Gynecology and Obstetrics (FIGO) staging for the prognosis of endometrial carcinoma patients. Methods This cohort study retrieved the data of 28,824 patients confirmed as endometrial carcinoma between 2010 and 2015 in the surveillance, epidemiology, and end results (SEER) database. COX risk proportional model was established to evaluate the association between FIGO staging with the all-cause mortality of endometrial carcinoma. The diagnostic value of FIGO staging and the new staging for the mortality of patients were evaluated by receiver operator characteristic curve (ROC). Hazard ratio (HR) and 95% confidence interval (CI) were effect size. Results The 5-year survival rate of all participants was 77.21%. The median follow-up time was 60.00 (60.00,60.00) months. Patients at FIGO staging IB (HR=1.75, 95% CI: 1.62–1.90), FIGO staging II (HR=2.22, 95% CI: 2.00–2.47), FIGO staging IIIA (HR=2.74, 95% CI: 2.43–3.09), FIGO staging IIIB (HR=4.07, 95% CI: 3.48–4.76), FIGO staging IIIC1 (HR=3.84, 95% CI: 3.52–4.20), FIGO staging IIIC2 (HR=4.52, 95% CI: 4.09–4.99), FIGO staging IVA (HR=5.56, 95% CI: 4.58–6.74), and FIGO staging IVB (HR=7.62, 95% CI: 6.94–8.36) were associated with increased risk of all-cause mortality of endometrial carcinoma patients. After adding positive lymph nodes as another covariate in Model 3, the effect on of FIGO staging survival was reduced when the FIGO staging was higher than stage III/IV. The C-index of the new staging 0.781 (95% CI: 0.774–0.787) was higher than FIGO staging 0.776 (95% CI: 0.770–0.783). Conclusion Our new staging using the number of positive lymph nodes supplement to the FIGO staging was superior than the FIGO staging for predicting the prognosis of endometrial cancer patients, which might help more accurately identify endometrial carcinoma patients who were at high risk of mortality and offer timely treatments in these patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Number of Positive Lymph Nodes and Survival in Endometrial Carcinoma: A Proposal for a Modified Staging

Li,

Zhang,

2024

IJWH

View full text Add to dashboard Cite

show abstract

“…About 25 % of patients are insensitive to platinum-based first-line therapies, and cancer cells are prone to drug resistance. However, the overall response rate is low after multi-line chemotherapy [3,4]. The second-line therapy of ovarian cancer has lower effectiveness and a relatively shorter maintenance time.…”

Section: Introductionmentioning

confidence: 99%

Efficacy of apatinib on advanced ovarian cancer patients who failed first and second-line chemotherapy

Wen¹,

Zhao²,

Li³

et al. 2023

Trop. J. Pharm Res

View full text Add to dashboard Cite

Purpose: To investigate the efficacy and safety of apatinib in the treatment of advanced epithelial ovarian cancer (EOC) patients who failed first and second-line chemotherapy. Methods: The clinical data of 100 patients diagnosed with advanced ovarian cancer were retrospectively analyzed. They were divided into two groups, with 50 patients in each group. One group was treated with apatinib mesylate (Apatinib group), while the other group was treated with gemcitabine (Gemcitabine group). Clinical efficacy, adverse reactions, and quality-of-life scores were were assessed, while the survival status of patients was recorded during follow-up. Results: After treatment, the objective response rate (ORR) and disease control rate (DCR) were 24.0 % (12/50) and 70.0 % (35/50) in Apatinib group, and 12.0 % (6/50) and 52.0 % (26/50) in Gemcitabine group. In terms of adverse reactions, the incidence of hand-foot syndrome and hypertension were significantly higher in Apatinib group than in Gemcitabine group, but the incidence of nausea and vomiting, anemia, neutropenia, and thrombocytopenia were significantly lower in Apatinib group than in Gemcitabine group (p < 0.05). Follow-up results revealed the median overall survival (OS) of patients to be 10.1 and 9.0 months, respectively, in Apatinib and Gemcitabine groups. Results of the log-rank test showed that OS in Apatinib group was significantly longer than that of Gemcitabine group. Conclusion: Apatinib demonstrates clear effectiveness and a superior safety profile than Gemcitabine in the management of patients with advanced ovarian cancer who did not respond effectively to multiple rounds of chemotherapy.

show abstract

Correlation Analysis of Immune Cell Infiltration in Recurrent Endometrial Carcinoma

Wang,

Liu,

Zheng

2023

j biomed nanotechnol

View full text Add to dashboard Cite

Numerous studies have established a close relationship between tumor progression, prognosis, and the infiltration of immune cells in the tumor microenvironment. This study aimed to investigate the differences in infiltrating immune cells between recurrent endometrial cancer and non-recurrent endometrial cancer. Firstly, gene expression data of endometrial cancer were obtained from the GEO database. Differential gene analysis using Geo2R identified significant gene expression differences, and KEGG and GO analyses were conducted on the qualified differential genes. Subsequently, CIBERSORT was employed to analyze the infiltration of 22 immune cell types in the tumor microenvironment, identifying differential immune cells. The results revealed significant differences in gene expression between recurrent and non-recurrent endometrial carcinoma. Interestingly, CIBERSORT analysis demonstrated a significant increase in monocyte infiltration in recurrent endometrial cancer compared to non-recurrent cases. Monocyte infiltration was found to play a crucial role in the progression of endometrial cancer recurrence. These findings provide valuable insights for clinicians to develop personalized treatment strategies for patients with recurrent endometrial cancer.

show abstract

Hysterectomy or/and lymphadenectomy for the survival of patients with primary endometrial cancer: a cohort study using the SEER database

Cited by 4 publications

References 26 publications

Number of Positive Lymph Nodes and Survival in Endometrial Carcinoma: A Proposal for a Modified Staging

Number of Positive Lymph Nodes and Survival in Endometrial Carcinoma: A Proposal for a Modified Staging

Efficacy of apatinib on advanced ovarian cancer patients who failed first and second-line chemotherapy

Correlation Analysis of Immune Cell Infiltration in Recurrent Endometrial Carcinoma

Contact Info

Product

Resources

About